<DOC>
	<DOCNO>NCT01846299</DOCNO>
	<brief_summary>To evaluate efficacy safety 0.5 mg Ranibizumab intravitreal injection adult patient visual impairment due macular edema ( ME ) .</brief_summary>
	<brief_title>To Assess Efficacy Safety Intravitreal Ranibizumab People With Vision Loss Due Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis active ME secondary cause ( adult patient : except diabetic macular edema ( DME ) , agerelated macular degeneration ( AMD ) retinal vein occlusion ( RVO ) ) ; BCVA must ≥ 24 ≤ 83 letter ; Visual loss mainly due presence eligible type ME . Women childbearing potential , Active malignancy ; History stroke less 6 month prior screen ; Uncontrolled systemic inflammation infection , relate directly underlie causal disease ME ; Active diabetic retinopathy , active ocular/periocular infectious disease active severe intraocular inflammation ; Any type advance , severe unstable ocular disease reatment ; ME high likelihood spontaneous resolution . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vision Impairment</keyword>
</DOC>